Is Pfizer Putting the Car-T Before the Horse?

Pfizer has moved to establish a good preclinical presence in a promising emerging cancer therapy class

Jun 19, 2014 at 5:01PM

Immuno-onocology is grabbing a large share of the headlines in oncology drug development these days and generating significant buzz for Big Pharma companies including Merck and Bristol-Myers Squibb. While Pfizer (NYSE:PFE) has not been seen as a leader in IO drug development, the company does have antibodies in development targeting IO targets like 4-1BB, OX-40, and PD-1. Now the company has added more shots on goal to its IO platform, striking a collaboration agreement with French biotech Cellectis to develop chimeric antigen receptor T-cell therapies, an unproven but high-potential emerging therapeutic class.

The deal
Pfizer and Cellectis announced on June 18 that they are forming a collaboration to develop chimeric antigen receptor T-cell (or CAR-T) therapies for cancer. Under this agreement, Pfizer will pay $80 million upfront and up to $185 million in milestones for each candidate that emerges from the collaboration (leading to a potential total of $2.86 billion). Pending Cellectis shareholder approval, Pfizer will also take a 10% stake in the company at EUR 9.25/share, which I believe works out to around $27 million based on the company's reported shares outstanding.

Through this deal, Pfizer will gain exclusive rights to 15 oncology targets; the two companies will cooperate on preclinical work and Pfizer will have subsequent development responsibility. Cellectis will also select 12 targets, with Pfizer funding the R&D costs for four of those and getting the right of first refusal for further development and marketing rights. No specifics were given about the targets in the initial release, though Cellectis is known to have identified multiple hematological and solid tumor targets for preclinical development.

CAR-Ts could be strong horses in the race
CAR-Ts are created by taking T-cells (a type of white blood cell) and adding chimeric antigen receptors that recognize antigens associated with a particular tumor type. The modified T-cells are then introduced into the patient, where they significantly enhance the immune system's ability to recognize and destroy cancer cells.

If this sounds familiar, it is very similar to the underlying principle behind Dendreon's (NASDAQ:DNDN) Provenge cancer vaccine. Provenge has demonstrated a roughly four-month median survival advantage in clinical trials, but has been a commercial disappointment. Some of the disappointment can be attributed to the strong clinical performance of new drugs from Johnson & Johnson and Medivation, but the need to collect dendritic cells from each patient and create a customized product has also been a limiting factor.

In contrast, Cellectis has been focusing on an allogenic approach that would not require the collection/extraction of each patient's own T-cells. Instead, this would be an "off the shelf" product that would be faster, easier, and cheaper to produce.

Multiple players already at work
The CAR-T therapeutic class is hardly mature, but that does not mean that Cellectis and Pfizer won't see competition. Novartis (NYSE:NVS) is arguably furthest along with CAR-T therapy development, with a very promising treatment for refractory B cell hematological cancers and strong initial responses in patients with pancreatic or ovarian cancer.

Juno Therapeutics has seen very strong initial results of its CAR-T therapy in non-Hodgkins lymphoma, though the treatment did go through a clinical hold after concerns about cytokine release syndrome. This cytokine release is in some respects a "feature" of how the therapy works, but excessive immune response may be a safety issue to watch in future CAR-T trials.

Beyond Novartis and Juno, Celgene and Bluebird Bio have partnered on CAR-T drug development, and Kite Pharma is also working in the space. Investors may also want to take note of companies developing T-cell receptor (or TCR) therapies, including Adaptimmune – a spin-off from Medigene that has partnered with Glaxo. Both Juno and Kite are also working on TCRs in addition to their CAR-T therapies.

The bottom line
Investors should not get too excited about any preclinical drug development agreement unless they happen to own the shares of the development-stage biotech that has garnered Big Pharma's attention. There have been many exciting new high-potential therapies that attracted multiple big-ticket development deals, only to founder and fail in clinical trials.

That said, CAR-T therapy looks like a high-potential opportunity and Pfizer has moved to tie up what looks like could be one of the stronger emerging technology platforms. It will most likely take 10 years or more for this collaboration to produce real revenue (if it ever does), but the excitement around IO is such that strong phase 2, or even phase1, data could be enough to boost Pfizer's multiple.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool owns and recommends shares of Johnson & Johnson, and recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers